IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (662)	4/17/1997 6:19:00 PM
From: Brad C. Dunlap	of 1762

HI Miljenko, Yes the results were very good as they were profiled and highlighted by the the college of Rheumatology as being one of the more promising therapies that were presented. Centocour did not recieve this notoriety from the ACR nor the individual rheumatologists that were in attendence. My comments on enthusiasm for CE9.1 came from being there and listening and questioning the rheumatologist,competitors,as well as Idec and Smithkline. I came away with even more excitement on not only what was formally presented as well as what was not formally stated. I think most investors who analyze management teams,products and companys do our best to seperate company hoopla from potential probability and fact so I do think your comment on the ABC's of knowing that managements true intent is to sell us the positives and minimize the negatives is very well understood. I do want you to know that I also appreciate your knowledge in the biotech field but it would be very easy for someone to put up many cautious flags and hints of worries in a company such as ISIP which has very little clinical support and great theory. Yes CE9.1 is approaching the finish line on a relative basis compared to a company like ISIP which is so very early and speculative relative to the progress and data that Idec/smithkline have presented. Don't get me wrong I personally think that there is much promise to antisense and a company like ISIP and am watching very closely, but if you want to critique on the same level as Idec my only comment is that there is tremendous speculation with world of potential pitfalls for such limited hard data that has been presented. I wish you tremendous success with ISIP and lets just watch what the future has in store for all biotechs.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next